In vitro studies have demonstrated that retinoic acid (RA) can alter the growth and morphologic characteristics of human neuroblastoma cells in a manner that is consistent with a reduced expression of the malignant phenotype. These effects may reflect the ability of this retinoid to promote celullar differentiation, thus causing neuroblastoma cells to acquire more neuron-like properties.
One aim of this project is to test this possibility. A number of well-characterized biochemical parameters will be investigated in association with RA treatment of human neuroblastoma cell lines. These experiments will further assess the ability of RA to induce physiologic-like qualities of maturation in neuroblastoma cells and will provide a means of establishing sensitive quantitative assays for assessing cellular maturation in our mechanistic studies. Results obtained by the in vitro assay systems will be further tested in an in vivo nude-mouse model to confirm and correlate RA-induced reduction in tumorigenicity and maturational processes. This in vivo model may also serve to emphasize the clinical potentials and limitations of RA treatment for control of neuroblastoma in humans. We will also attempt to define neuroblastoma phenotypes that vary in their sensitivity to RA treatment. As such, the responses of cells to RA will be compared wih their reactivity to a variety of monoclonal antibodies. Monoclonal antibody reactivity with the neuroblastoma cells will also be evaluated during RA treatment in an effort to define a general """"""""profile"""""""" of RA-induced antigenic changes that occur. In a clinical setting, such use of monoclonal antibodies would allow for the identification of neuroblastoma phenotypes that vary in RA treatment responses and prognosis, and provide a convenient means of following in vivo tumor-cell maturational processes. Finally, we will initiate mechanistic studies for assessing the molecular action of RA on neuroblastoma cell differentiation based upon the following areas of investigation: 1) the interrelationship between RA and the cyclic AMP system; 2) RA regulation of a putative neuroblastoma oncogene (N-myc); and 3) RA-induced changes of a cellular tumor antigen (termed p53) that has been implicated in the control of cell division and differentiation processes. Results of these studies should provide a basis for future in-depth investigations into deliniating the molecular mechanisms of RA on tumor cell differentiation using human neuroblastoma as a model system.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA043503-01
Application #
3185698
Study Section
Neurology C Study Section (NEUC)
Project Start
1986-05-01
Project End
1988-04-30
Budget Start
1986-05-01
Budget End
1987-04-30
Support Year
1
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Barua, Arun B; Sidell, Neil (2004) Retinoyl beta-glucuronide: a biologically active interesting retinoid. J Nutr 134:286S-289S
Tuthill, Matthew C; Wada, Randal K; Arimoto, Jason M et al. (2003) N-myc oncogene expression in neuroblastoma is driven by Sp1 and Sp3. Mol Genet Metab 80:272-80
Sidell, N; Pasquali, M; Malkapuram, S et al. (2003) In vitro and in vivo effects of easily administered, low-toxic retinoid and phenylacetate compounds on human neuroblastoma cells. Br J Cancer 89:412-9
Han, S; Wada, R K; Sidell, N (2001) Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor gamma. Cancer Res 61:3998-4002
Sawatsri, S; Samid, D; Malkapuram, S et al. (2001) Inhibition of estrogen-dependent breast cell responses with phenylacetate. Int J Cancer 93:687-92
Han, S W; Greene, M E; Pitts, J et al. (2001) Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARgamma) in human neuroblastoma cells. Clin Cancer Res 7:98-104
Sidell, N; Sawatsri, S; Connor, M J et al. (2000) Pharmacokinetics of chronically administered all-trans-retinoyl-beta-glucuronide in mice. Biochim Biophys Acta 1502:264-72
Sidell, N; Chang, B; Yamashiro, J M et al. (1998) Transcriptional upregulation of retinoic acid receptor beta (RAR beta) expression by phenylacetate in human neuroblastoma cells. Exp Cell Res 239:169-74
Connor, M J; Sidell, N (1997) Retinoic acid synthesis in normal and Alzheimer diseased brain and human neural cells. Mol Chem Neuropathol 30:239-52
Wada, R K; Pai, D S; Huang, J et al. (1997) Interferon-gamma and retinoic acid down-regulate N-myc in neuroblastoma through complementary mechanisms of action. Cancer Lett 121:181-8

Showing the most recent 10 out of 33 publications